Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer

Sponsor
Region Skane
Study ID
NCT00804830
Phase
PHASE2
Status
Terminated

Conditions

  • Carcinoma
  • Metastatic Cancer
  • Thyroid Cancer
  • Thyroid Neoplasms

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w

Study Details

Anaplastic Thyroid Cancer is a very aggressive disease. The investigators believe that angiogenesis is very important for these tumors to progress. Preclinical data is suggesting this. This is why we we prospectively want to treat these patients with avastin (and doxorubicin). However, local control is of major concern. Therefore, patients are initially treated with hyperfractionated radiotherapy and undergo surgery. Then they can enter this study.

Key Dates

First listed
Dec 9, 2008
Start date
Apr 30, 2008
Status verified
Aug 2018
Primary completion
Dec 31, 2012
Completion
Dec 31, 2014

Study Design

Enrollment
15 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: chemotherapy
    Treatment with Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w for 6 months.

Primary Outcome Measure

Overall Survival [ Time Frame: 2-5 years ]

Related Studies